Tusamitamab ravtansine

Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8[1][2][3].

Product Specifications

CAS Number

[2254086-60-5]

Product Name Alternative

SAR-408701; HuMAb2-3-SPDB-DM4

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tusamitamab-ravtansine.html

Purity

99.42

Solubility

10 mM in DMSO

Smiles

[Tusamitamabravtansine]

Molecular Weight

148000 (average)

References & Citations

[1]Gazzah A, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33 (4) :416-425.|[2]Lorenzo Belluomini, et al. Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. Cancers (Basel) . 2023 Nov 10;15 (22) :5368. |[3]Ye-Jin Kim, et al. Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. Front Oncol. 2023 Feb 27:13:1124039.